Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies on the serotonin transporter in platelets.

S Z Langer1, A M Galzin

  • 1Départment de Biologie, Laboratoires d'Etudes et de Recherches Synthélabo, Paris, France.

Experientia
|February 15, 1988
PubMed
Summary

[3H]-Imipramine and [3H]-paroxetine binding sites on the serotonin transporter in platelets may differ from serotonin's binding site. Decreased [3H]-imipramine binding in platelets of depressed patients suggests a potential biomarker for depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic use of release-modifying drugs.

Handbook of experimental pharmacology·2007
Same author

Synthesis and SAR of 3- and 4-substituted quinolin-2-ones: discovery of mixed 5-HT(1B)/5-HT(2A) receptor antagonists.

Bioorganic & medicinal chemistry·2001
Same author

Effects of SL 65.0472, a novel 5-HT receptor antagonist, on 5-HT receptor mediated vascular contraction.

European journal of pharmacology·2000
Same author

Role of alpha1-adrenoceptors in the future treatment of urological diseases.

European urology·1999
Same author

History and nomenclature of alpha1-adrenoceptors.

European urology·1999
Same author

Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas.

Journal of affective disorders·1999

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • The serotonergic transporter (SERT) plays a crucial role in regulating serotonin levels.
  • Blood platelets possess a recognition site associated with SERT, which can be labeled by radioligands like [3H]-imipramine and [3H]-paroxetine.

Purpose of the Study:

  • To investigate the characteristics of the [3H]-imipramine and [3H]-paroxetine binding sites on platelet SERT.
  • To explore the relationship between ligand binding and serotonin uptake inhibition.
  • To assess the potential of [3H]-imipramine binding as a biological marker for depression.

Main Methods:

  • Radioligand binding assays using [3H]-imipramine and [3H]-paroxetine.
  • Dissociation kinetic experiments.
  • Comparison of binding parameters in platelets from depressed patients and healthy volunteers.

Main Results:

  • [3H]-Imipramine and [3H]-paroxetine bind with high affinity to a site associated with platelet SERT.
  • Ligand binding affinity strongly correlates with the potency of drugs to inhibit serotonin uptake.
  • Dissociation kinetics suggest distinct sites for serotonin and modulatory ligands.
  • Reduced Bmax of [3H]-imipramine binding observed in platelets of untreated depressed patients compared to controls.

Conclusions:

  • The binding site labeled by [3H]-imipramine and [3H]-paroxetine on platelet SERT may be distinct from the serotonin substrate recognition site.
  • [3H]-Imipramine binding in platelets appears to be a state-dependent biological marker for depression.

Related Experiment Videos